Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

This study has been completed.
Sponsor:
Information provided by:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT00180024
First received: September 9, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

The hypothesis is tested that stimulation with angiotensin II after blockade of the AT1-receptor results in venodilation in human healthy subjects in vivo.


Condition Intervention
Healthy Subjects
Drug: irbesartan (drug)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training

Resource links provided by NLM:


Further study details as provided by Technische Universität Dresden:

Study Start Date: January 2002
Estimated Study Completion Date: September 2005
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy subjects

Exclusion Criteria:

  • any relevant disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180024

Locations
Germany
Institute of Clinical Pharmacology, Medical Faculty, University of Technology
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Investigators
Study Chair: Wilhelm Kirch, MD Institute of Clinical Pharmacology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00180024     History of Changes
Other Study ID Numbers: IKPD 01-02
Study First Received: September 9, 2005
Last Updated: September 9, 2005
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Technische Universität Dresden:
AT1-receptor
AT2-receptor
human pharmacology

Additional relevant MeSH terms:
Irbesartan
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 21, 2014